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Abstract: Traumatic brain injury (TBI) is one of the world’s leading causes of morbidity and mortality
among young individuals. TBI applies powerful rotational and translational forces to the brain
parenchyma, which results in a traumatic diffuse axonal injury (DAI) responsible for brain swelling
and neuronal death. Following TBI, axonal degeneration has been identified as a progressive process
that starts with disrupted axonal transport causing axonal swelling, followed by secondary axonal
disconnection and Wallerian degeneration. These modifications in the axonal cytoskeleton interrupt
the axoplasmic transport mechanisms, causing the gradual gathering of transport products so as
to generate axonal swellings and modifications in neuronal homeostasis. Oxidative stress with
consequent impairment of endogenous antioxidant defense mechanisms plays a significant role in
the secondary events leading to neuronal death. Studies support the role of an altered axonal calcium
homeostasis as a mechanism in the secondary damage of axon, and suggest that calcium channel
blocker can alleviate the secondary damage, as well as other mechanisms implied in the secondary
injury, and could be targeted as a candidate for therapeutic approaches. Reactive oxygen species
(ROS)-mediated axonal degeneration is mainly caused by extracellular Ca2+. Increases in the defense
mechanisms through the use of exogenous antioxidants may be neuroprotective, particularly if they
are given within the neuroprotective time window. A promising potential therapeutic target for DAI
is to directly address mitochondria-related injury or to modulate energetic axonal energy failure.
Keywords: traumatic brain injury; oxidative stress; reactive oxygen species; immunohistochemistry;
biomarkers
1. Introduction
Traumatic brain injury (TBI) can result in long-term damage in as many as 50% of affected
individuals [1]. It is estimated that in 2020, TBI will become the third leading cause of permanent
disability and mortality worldwide [2], with major economic implications for national health systems:
in the United States alone, it is estimated that 1.7 million persons will suffer from TBI each year with
an estimated expense of 60 billion dollars for specific medical treatments [3,4].
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TBI is one of the most frequent causes of traumatic axonal damage, commonly known as diffuse
axonal injury (DAI). While the first descriptions of experimental models of the diffuse morphological
abnormalities of the white matter linked to shear and tensile forces on brain parenchyma were reported
in the 1940s [5,6], Strich, in a classical paper from 1956 [7], was the first to fully recognize and
describe the histopathological appearance of the white matter after severe traumatic brain injury.
Adams [8,9] introduced the term “diffuse axonal injury”. He classified DAI in a three-step grading
system, according to the extent of axonal damage.
The introduction of the high-field magnetic resonance imaging (MRI) [10] and the improvement of
immunostaining techniques [11] shed light on the mechanisms underlying DAI. A deeper knowledge
of the physiopathology as well as a deeper understanding of the risk factors associated with poor
clinical outcomes have improved functional and neurological prognosis of patients suffering from
DAI [1].
Yet DAI itself, as well as another condition belonging to the neurotrauma family, chronic
traumatic encephalopathy (CTE) [12,13], still appears to be extremely heterogeneous and elusive
clinicopathological entities per nature [11], and complete knowledge of these conditions seems some
way off. Oxidative stress plays a critical role in the genesis of the dramatic clinical phenotypes of DAI
that seem to be unavoidably linked to the effects of a plethora of post-traumatic molecular and cellular
changes, for instance, the imbalance between the production and removal of ROS, the releasing and
activation of pro-inflammatory cytokines, and modifications in calcium metabolism. The translational
and clinical research on DAI is producing an outstanding amount of evidence in a surprisingly
fast time.
Therefore, the aim of this literature review is to identify and encompass all the relevant, strongest
and most recent evidence in the pathophysiological, diagnostic and clinical aspects of acute DAI,
with a special focus on the translational aspect of the most recent findings into specific diagnostic
and prognostic benchmarks, in order to outline and discuss the factors leading to a poor functional
and neurological prognosis of patients suffering from DAI, with special attention on connecting
the preclinical and clinical aspects, along with the diagnostic implications in the management of
this condition.
2. Mechanism of Injury
DAI, as far as current evidence suggests, is thought to be one of the main causes of post-traumatic
loss of consciousness in the absence of detectable intracranial lesions on computed tomography (CT) [8].
It represents the morphological correlate of a rotational acceleration-deceleration traumatic brain injury
through strain or shearing forces [14,15]. During a traumatic brain injury the brain is subjected to
a multitude of forces, such as rotational, tensile and compressive stresses; the inertia of the brain
leads to a dissociation between its relative movement and the cervical column, thus, when a rapid
movement of the head is generated during trauma without a significant physical impact, translational,
rotational and/or angular acceleration can lead to blood vessels stretching or to axonal damage, mostly
in the case of rotational acceleration [16]. In this case, the damage affects the planes between tissues of
different density (the grey-white matter junction), and the rotational center of mass in the intracranial
space (the rostral brain stem) [17].
Experimental Models
Due to the structural complexity of the human brain it is difficult to replicate the entire spectrum
of dynamic forces acting in human DAI pathophysiology. Several animal models have been developed,
such as open-head injury models like fluid percussion (FP) [18] and controlled cortical impact (CCI)
systems [19,20], in which the mechanical force is applied directly to the dura mater exposed by
a craniotomy, and closed-head injury (CHI) models in which the damage is induced by direct impact
(for example striking the intact skull with a piston or dropping a weight on the intact skull), non-impact
(blast) or inertial loading (by rapid rotation of the head in various planes) [21]. The DAI mechanism is
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presumably similar to those investigated in the aforementioned injury models, although open head
models are focused on the fine axonal effects of mechanical trauma.
A recent neurotrauma model system called CHIMERA (Closed-head impact model of engineered
rotational acceleration) has been developed by Namjoshi et al. in order to integrate biochemical,
behavioral and neuropathological analyses after delivery impacts of defined energy to a closed
skull with unconstrained head motion after impact, making this model suitable to investigate the
pathophysiology of TBI [22].
Although it has been experimentally shown that acceleration/deceleration forces are sufficient for
producing injury, in the real world the direct impact almost always comes first [11]. While subdural
hematomas occur more frequently in falls on a firm surface, DAI is seen in vehicle occupants where
impact on deformable surfaces prolongs and reduces the rate of deceleration. In DAI, the force of
the initial impact does not need to be strong enough to cause skull fractures, but it is still capable of
producing a diffuse brain injury.
An essential factor in the development of shear strain is the direction of the head movement: coronal
head movement is associated with more severe diffuse damage than sagittal head movement [15].
Summary: DAI represents the morphological correlate of a rotational acceleration-deceleration
traumatic brain injury. Although several models have been proposed the complexity of in vivo
condition are extremely difficult to reproduce.
3. Physiopathology
Traumatic injury causes dynamic deformation of the brain parenchyma; as a consequence, there
is a risk of stretch and shear injuries of axons and blood vessels. Due to their viscoelastic nature,
white matter axons are susceptible to damage by high strain rates produced during traumatic brain
injury [23]. Following a TBI, axonal degeneration is identified as a progression from disruption in
axonal transport leading to axonal swelling, followed by secondary disconnection and Wallerian
degeneration. These modifications in the axonal cytoskeleton interrupt the axoplasmic transport
mechanisms, causing the gradual gathering of transport products to generate axonal swellings and
modifications in neuronal homeostasis. The initial impact of the brain causes focal perturbation in the
axon, resulting in an alteration of the axonal transport and an accumulation of the β-amyloid precursor
protein (β-APP), a transmembrane glycoprotein widely represented in the membranous structures of
the central nervous system, which can be detected within 2 h after damage [24]. The accumulation of
this precursor is common in other conditions [12].
DAI is not only caused by primary axotomy from mechanical forces, but also from secondary
axotomy due to a progressive molecular and cellular cascade of pathologic changes within the axon
after initial shear stress at the time of injury [25]. Some studies support the role of an altered axonal
calcium homeostasis in the mechanism of the secondary damage to the axon, neuron and vessel [26],
and suggest that the calcium channel blocker, nimodipine can alleviate the secondary damage, which
as well as other mechanisms implied in the secondary injury, could be targeted as a candidate for
therapeutic approaches [17,22].
The altered calcium homeostasis is the consequence of the release of glutamate and other
excitatory amino acids, and of neuron mechanical perturbations that lead to mechanoporation of
the cell membrane. Calcium is involved in the activation of caspases and calpains, that play a role in
the initiation of necrosis and apoptosis. Furthermore, the generation of free radicals and the release of
hydrolytic enzymes from lysosomes have a role in cytotoxic cascades [17].
The neuroinflammatory response also contributes to the mechanism of damage. In DAI experimental
models the immune response of microglial cells in the central nervous system has been frequently
investigated. Venkatesan et al. [27] used Galectin-3/Mac-2 as a marker of a subpopulation of activated
microglia involved in myelin degradation, suggesting an important role in the pathogenesis of DAI.
In a study by Oehmichen et al. [28] using an immunohistochemical double-labeling technique, β-APP
and CD68 have been detected for axonal alteration and for microglia infiltration respectively. β-APP
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and CD68 co-localization in half of the patients 5– 15 days after injury demonstrates the presence of
microglial infiltration in areas of axonal alteration.
Other studies have demonstrated the involvement of cytokines in neuroinflammation, such as
IL-1α, IL-1β [29], IL-6 [30], Tumor Necrosis Factor (TNF)-α [31], and adhesion molecules such as
ICAM-1 and chemokines (MCP-1) [32,33].
Summary: β-APP accumulation, calcium homeostasis dysregulation and neuroinflammatory
responses linked to cytokine activation concur with the pathophysiology of neuronal death in TBI.
4. TBI and Oxidative Stress
DAI, as a type of TBI, is associated with cytoskeletal alterations, represented by swellings or
varicosities along the axons and terminal bulbs [34–36]. These axonal alterations may be caused
by mechanical disruption, and subsequent increasing intracellular Ca2+ influx by the breaches in
the axolemma [37–39]. In this process transmembrane active transport by Ca2+ channels could
also be implicated. Excess intracellular Ca2+ may be driven in the mitochondria, where reactive
oxygen species (ROS) are generated, inducing oxidative stress into the axon [37]. Oxidative stress is
an event caused by the imbalance between biochemical processes leading to the production of ROS
and those responsible for the removal of ROS, known as the enzymatic and non-enzymatic antioxidant
cellular defense systems. The excessive production of ROS due to excitotoxicity and depletion
of the endogenous antioxidant system induces peroxidation of cellular and vascular structures,
protein oxidation, and inhibition of the mitochondrial electron transport chain [40], causing oxidative
cellular damage.
4.1. Role of Mitochondria and Calcium
Mitochondria are the main cellular consumers of oxygen and hold numerous redox enzymes
capable of transferring single electrons to oxygen, generating ROS superoxide (O2−). Mitochondria also
carry a large antioxidant defense system to detoxify the ROS produced by the reactions we are going
to describe. The transfer of electrons to oxygen, generating superoxide, is more probable when these
redox carriers are in great quantity charged with electrons and the potential energy for transfer is high,
as reflected by a high mitochondrial membrane potential. ROS generation is reduced when available
electrons are few and potential energy for the transfer is low. Non-enzymatic components of the
system principally include tocopherol, coenzyme Q10 and glutathione (GSH). Enzymatic components
include manganese superoxide dismutase catalase, glutathione peroxidase, glutathione reductase (GR)
and others. The regeneration of GSH (through GR) depends on Nicotinamide Adenine Dinucleotide
Phosphate (NADPH), which is derived from substrates or the membrane potential. So, like ROS
generation, antioxidant defenses are dependent on the redox and energetic state of mitochondria.
In intact mitochondria, a large antioxidant defense capacity balances ROS generation, and there
is little ROS production. Mitochondrial damage with the decrease of antioxidant defense capacity
is a precondition for ROS production. Once this occurs, a vicious cycle can result by which ROS
can further damage mitochondria, causing more free-radical formation and loss or consumption
of antioxidant capacity [41] with the generation of oxidative stress that causes damage to cellular
structures. Studies over the last two decades suggest that free radical generation and oxidative damage
plays a significant role in post-traumatic secondary injury after TBI [42], particularly to neuronal
structures such as axons. After axonal damage, an increase in intracellular Ca2+ occurs, primarily
derived from release of the intracellular pool and dysregulation of Ca2+ metabolism [43,44]. Increases
in cytoplasmic Ca2+ determine mitochondrial Ca2+ sequestration, resulting in ROS generation and
oxidative stress [37]. In the work of Johnson et al. the ionic derangement following axonal trauma
has been hypothesized as playing a pivotal role in post-injury, in both axonal degeneration and the
persistent dysfunction of otherwise intact axons [36]. In particular, it was thought that high amounts
of intra-axonal Ca2+ play a central role in the secondary damage to axons following mechanical
deformation [45–49]. Maxwell et al. established indirect proof of post-traumatic calcium influx into
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axons via changes in calcium-ATPase activity after optic nerve stretch injury [50–52].Also, utilizing
an in vitro axon stretch model, explicit visual evidence of calcium entry into axons immediately
following trauma has been demonstrated [53]. According to Büki et al., DAI is produced by focal
perturbations of the axolemma, permitting calcium influx to trigger local intra-axonal cytoskeletal
and mitochondrial modifications that generate cyto-c release and the activation of the caspase enzyme
cascade in axons. It has been hypothesized that this mitochondrial damage creates local bioenergetic
failure, causing axonal failure and disconnection [54]. Mitochondria appear to play a critical role in the
secondary injury that occurs after TBI [55,56], and mitochondrial dysfunction has been shown to be
involved in excitatory amino acid-induced neurotoxicity [57–60]. Increased Ca2+ concentration also
causes an increased release of excitatory neurotransmitters [61], with resultant caspase activation [62,63]
and distal axonal degeneration [64]. Axonal spheroid formations originate from axonal swellings [65]
in axons undergoing oxidative stress [66] and have been associated with an increase in neuronal Ca2+,
ROS production, impaired mitochondria and protease activation [65,67,68]. In particular, increase in
neuronal Ca2+ [69] has a key role in neurodegeneration. In the work of Barsukova, an adult mouse
model of was used to investigate the role of Ca2+ and ROS in the configuration of axonal spheroids and
cytoskeletal changes. ROS-mediated axonal changes are mainly caused by extracellular Ca2+. Removal
of extracellular Ca2+, rather than blockade of mitochondrial Ca2+ release, is an efficient strategy in
lowering intracellular Ca2+ and inhibiting spheroid formation [66,70].
4.2. Role of Mitochondrial Membrane Permeability
Mitochondrial impairment has a relevant role in determining axonal alteration, by ROS production
and mitochondrial permeability transition pore (mPTP) generation [71]. mPTP is an internal membrane
protein, generated as a consequence of Ca2+ gathering, that permits mitochondrial influx and
efflux [72,73]. Buki et al. used a rodent model in an experiment that explored the primary neurons of
impact acceleration head injury. This underlined that associated with calpain activation, the related
axonal cytoskeleton and organelles also demonstrated change consistent with calcium overloading as
reflected in neurofilament sidearm modification and compaction, and local mitochondrial swelling
with disruption of their cristae. They proposed that such mitochondrial perturbation was a terminal
event in the local death of the axon [54]. It was recognized that mitochondrial swelling was fully
coherent with a calcium induced opening of the mPTP and they supported this thesis through the use
of cyclosporin-A, an inhibitor of the mPTP, which provides mitochondrial protection and cytoskeletal
changes [74–77]. Cyclosporin A, a drug that binds and inhibits cyclophilin D, provided some interesting
but not definitive results. Cyclophilin D is a protein complex involved in the modulation of mPTP77 in
DAI models, inhibiting mPTP activation. Cyclosporin A failed to reduce axonal swelling in neurons
exposed to ROS [66], but mitigates cytoskeletal and axonal alterations [78].
The role of intra- and extracellular Ca2+ in elevating axoplasmic concentration, in response to H2O2
exposition, has been studied by Barsukova in an adult mouse model. In this study, during exogenous
oxidative stress the lack of extracellular calcium did not affect axoplasmic Ca2+ concentration, while
generation of mPTP permitted Ca2+ mitochondrial release [69]. As a result, the lack of extracellular
calcium associated with the application of cyclosporin A, completely abolished increases in axoplasmic
Ca2+ [79]. These results demonstrate that extracellular Ca2+ and mPTP activation have a primary and
a secondary role, respectively, in determining axonal alterations in response to ROS [66].
Inhibition of the formation of the mPTP has been described as a means prevent cytoskeletal
changes and axonal degeneration subsequent to in vivo impact acceleration brain injury [54,75,76,80].
4.3. Oxidative Stress, Calcium Influx and Calpain Activation
In a study by Yamada et al. [81], the relation between oxidative stress, calcium influx and calpain-1
activation in primary neurons was investigated. The calpains are calcium-regulated cysteine proteases
involved in ruling cell death pathways. Yamada demonstrated the probable molecular machinery of
calpain-1 isoform in apoptosis and proved that it plays a practical role in the regulation of extracellular
Int. J. Mol. Sci. 2017, 18, 2600 6 of 20
calcium influx and apoptosis in primary neurons exposed to oxidative stress. Oxidative stress causes
calcium release, which activates calpain-1. Activated calpain-1 mediates further Ca2+ entry, generating
a positive feedback loop. Then, activated calpain-1 induces mPTP and releases the apoptosis inducing
factor (AIF) from mitochondria. Caspase-3 is also activated by Calpain-1. The released AIF and
activated caspase-3 together induce DNA fragmentation and apoptosis [81]. Associated with calpain
activation, the related axonal cytoskeleton and organelles also demonstrated alterations consistent with
calcium overloading as reflected in neurofilament sidearm modification and compaction, microtubular
loss, and local mitochondrial swelling with disruption of their cristae, with the hypothesis that
such mitochondrial perturbation was a conclusive phenomenon in the local death of the axon [54].
Activated calpain proteolyzes large groups of cellular proteins, varying from structural proteins to
membrane-bound proteins (receptors, channels) and soluble proteins (enzymes and apoptotic proteins),
to nuclear transcription factors. Changing either or both the structure or activity of the protein
substrates can have important effects, from regulating signal transduction to axonal deterioration and
neuronal death (Figure 1) [82].
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Figure 1. Hypothetical inter-relationship between (traumatic brain injury) TBI-induced oxidative
damage and neurodegeneration. Secondary injury cascade in TBI induces oxidative stress related to
increase of free radicals reactive oxygen species/ ti e nitrogen species (ROS/RNS) and increase
calcium entry both fr m intracellular stores and injury-induced increases in glutamate (exci otoxicity).
Oxidative stress induces cell membrane ipoperoxidati n and calcium re ease, which activates
calp in. ROS nd RNS induced oxidative damage in neuron l mitochondria and compromise Ca2+
homeostasis. Activated calpain mediates further Ca2+ entry, forming a positive feedback loop and
induces mitochondrial membrane permeability and releases the apoptosis inducing factor (AIF) from
mitochondria. Caspase-3 is also activated by Calpain-1. The released AIF and activated caspase-3
together induce neurodegeneration. Activated calpain proteolyzes large groups of cellular proteins
varying from structural proteins and soluble proteins (e.g., apoptotic proteins). Changing either or both
the structure or activity of the protein substrates can have important effects such as axonal deterioration
and neuronal death.
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Summary: oxidative stress, caused by the post-traumatic imbalance between the ROS production
and degradation plays a critical role in axonal and neuronal damage.
5. Pathological Anatomy and Morphologic Findings
5.1. Macroscopic Findings
The structural features of DAI were defined by Adams et al. [8,83] using a series of 45 fatal cases.
In its most severe form, DAI has three distinctive structural features:
1. Diffuse supratentorial damage to axons (grade I)
2. A focal lesion in the corpus callosum (grade II)
3. A focal lesion or lesions in the rostral brain stem (grade III).
The focal lesions can often be identified macroscopically postmortem. They are usually hemorrhagic
in patients with short survival, but they are difficult to identify at necropsy because they become shrunken
scars; nevertheless, they are often brown in color because of the persistence of hemosiderin [8].
The lesion in the corpus callosum typically occurs in its inferior part and to one side of the
midline. If it extends to the midline there is often disruption of the interventricular septum with
an intraventricular hemorrhage.
The lesions of the rostral brain stem characteristically localize in the dorsolateral quadrant or
quadrants adjacent to a superior cerebellar peduncle.
The axonal damage can be seen only on microscopical examination. In these cases, the diagnosis
of DAI cannot be made without adequate histological studies [83,84].
If a patient with DAI survives for several months, the loss of bulk of the white matter causes
a progressive enlargement of the ventricular system and at a postmortem examination it could be
confused with post-traumatic hydrocephalus [8].
5.2. Microscopic Findings
The diagnosis of DAI must be confirmed by the microscopic finding of damaged axons: the swollen
axonal varicosities and the axonal bulbs. The two main attributes in the pathological diagnosis of DAI
are (1) the presence of diffuse/multifocal axonal damage in the white matter and (2) the fact that it is
widespread in many brain regions, of which at least one should be located above and one below the
tentorium [11].
The axonal damage takes three forms depending on the duration of survival. In their experimental
studies on primates, Gennarelli et al. [15,83] graded axonal injury into three grades of severity:
• Grade 1: there is scattered axonal retraction balls in the parasagittal white matter of the cerebral
hemispheres, the corpus callosum, the brain stem and, less commonly, the cerebellum
• Grade 2: in addition to axonal damage in the white matter of the cerebral hemisphere, there is
a focal lesion in the corpus callosum
• Grade 3: in addition to axonal damage in the white matter of the hemispheres, the focal lesions
are present in the dorsolateral quadrant of the rostral brain stem and the corpus callosum.
They concluded that the amount and distribution of axonal damage correlated well with the
duration and severity of coma and the eventual outcome. On the basis of the time of survival, there are
some characteristic features: the presence of a large number of axonal swellings in the white matter of
the corpus callosum and the dorsolateral quadrant of the rostral brain stem as well as the white matter
of cerebral hemispheres, cerebellum and brain stem, showed in patients with short-term survival rates
(days); the small clusters of microglia throughout the white matter in patients of intermediate-term
survival rates (weeks) ; the occurrence of Wallerian-type degeneration in the white matter throughout
the cerebral hemispheres, the brain stem and the spinal cord, as a typical feature in patients who
survive for many months [8].
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Recently, Hill et al. pointed out that the term “retraction bulbs” is not exhaustive of the classical
histological finding since the typical morphology is linked to the dysfunctional axonal transport rather
than axonal retraction. Again, the previously defined “retraction ball” should be named “axonal bulb”
to describe abnormal axonal profiles with a large single swelling [85]. Routinely, tinctorial stains,
such as hematoxylin and eosin or silver impregnation techniques have been used to diagnose typical
TBI features.
5.3. Immunohistochemistry and Stainings
Today, the gold standard for immunohistochemistry in DAI cases is the search forβ-APP (Figure 2).
It has been demonstrated that finding damaged axons occurs within 12–24 h, so in cases with a short
survival time it is difficult to detect DAI using conventional techniques, such as hematoxylin-eosin
staining, which can identify the axon injury after about 24 h, and methods using impregnation
with silver, which can reveal axon damage 12–18 h after the injury [83,86]. A immunohistochemical
technique that uses antibodies against β-APP allows identification of damaged axons a 2–3 h after
injury [87–89].
β-APP expression is an indicator of axonal injury, but it is not possible to distinguish between
traumatic mechanisms injuries and damage due to ischemia/hypoxia. As a consequence, DAI cannot
be assumed as a specific feature of mechanical injury alone.
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Figure 2. (A) Scattere axo al retraction balls stained with Congo Red (arrows), scale bar: ×250;
(B) diffuse β-APP positivity expression in the corpus callosum is an indicator of axonal injury
(grade II), scale bar: ×80; (C) β-APP (brown reactions) reaction exhibited a strong positive reaction
typically occurring in the dorsolateral quadrant or quadrants adjacent to a superior cerebellar peduncle
(grade III), scale bar: ×100; (D) morphological features of neuronal apoptosis (green) associated with
marked condensation of chromatin and its fragmentation into discrete bodies (arrows), scale bar: ×250.
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Niess et al. [14] examined 450 non-selected human brains in order to estimate the overall
incidence of DAI, assessing the axonal damage identifying β-APP in samples from pons and cerebrum.
They stated that the biomechanical mechanisms in the trauma group are responsible for the presence
of axonal damage mainly in the pons area, which is different to the more generalized pathomechanism
in the intoxication group, which showed a much higher extent of axonal damage in both pons
and cerebrum. Hayashi et al. [90] examined whether there are differences in the morphological
pattern of axonal bulbs in trauma and hypoxia in sections of corpus callosum immunostained
for β-APP. They found two different patterns. Similar investigations have been carried out by
Oehmichen et al. [91] and Graham et al. [92] in order to find characteristic patterns and distributions
of damaged axons that could indicate a traumatic origin of lesions.
5.4. Biomarkers
The processes characterizing DAI physiopathology determine the presence of potential biomarkers
for monitoring specific processes, assessing the severity of the injury, and also developing new
therapeutic strategies. A promising potential therapeutic target in DAI is direct to address mitochondria
related injury or to modulate energetic axonal energy failure. As previously mentioned, caspase and
calpain are calcium-dependent enzymes with a primary role in cytoskeletal alteration. Their activity
causes the production of several proteolytic products, potentially considered as biomarkers of DAI,
and extraordinarily important for the management of TBI (Table 1). In vivo, the inhibition of calpain
and calcineurin is able to mitigate axonal degeneration. αII spectrin breakdown products (SBDP145,
SBDP150, SBDP120) [93] derived from the cleavage of αII spectrin, a cytoskeleton component that
stabilizes the nodal structure of myelinated axons. Some reports have demonstrated an elevation of
αII spectrin and SBDPs after mechanical injury [94–96]. SBDPs increase within 6 h after injury and
reach a peak in 2–3 days in cerebrospinal fluid (CSF). SBDPs have been found in other central nervous
system injury of various origin [97], but they reach higher levels in TBI than in any other CNS disorder
associated with raised ICP.
Another cytoskeletal injury marker is represented by neurofilament protein (NF), which undergoes
proteolysis by caspase and calpain [98]. NF subunits have been found in the corpus callosum
of TBI patients [96]. A recent study by Shibahashi et al. [99] investigated the usefulness of serum
phosphorylated neurofilament heavy subunit (pNF-H) at 24 and 72 h after TBI, as a predictive marker
for the outcome (vegetative state or death) of patients at 6 months. Conversely, Neurofilament Light
chain (NF-L) protein serum level has been recently advocated as a potentially promising predictor of
the 12 months neurological outcome of patients with an MRI demonstrated DAI [100]. This evidence,
being inferred from relatively small samples of patients, deserves further confirmation by more
extensive prospective trials.
Also, GFAP [101], microtubule-associated protein tau [102,103] and amyloid β peptide (Aβ42) [104]
have been proposed as diagnostic and prognostic biomarkers in traumatic brain injury (TBI).
Bogoslovsky et al. [105] recorded levels in plasma from the acute through subacute stages after
TBI (24 h, 30 days and 90 days after the TBI). The levels were maximal at 24 h for GFAP and tau and
at day 30 for Aβ42. GFAP, tau and Aβ42 increased up to 90 days after TBI compared with controls.
A combination of all three biomarkers at 24 h and 30 days was found to be useful in both acute and
subacute phases of TBI.
Others potential biomarkers of DAI are represented by S-100β protein and neuron specific
enolase (NSE) [106]. S-100β is an acidic calcium binding protein [107] intensively investigated in
severe head injury [108,109]. Increase of S-100β has been described in the early phase of injury
in glial and Schwann cells, but S-100β cannot diffuse across the intact blood–brain barrier (BBB),
so its serum concentrations depend on BBB permeability [110]. Conversely, recent evidence from
others authors [111] focused attention on the contribution of an altered BBB, and did not confirm its
role in influencing S-100β serum levels. Moreover, an elevation of S-100β in polytrauma could be
a consequence of musculoskeletal trauma. Therefore, interpretation of S-100β should be considered
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with caution in polytrauma patients [112], notwithstanding that the effect of multi-trauma on S-100β
has been found to be limited to the first 12 h [113]. In a study with ninety-two patients with severe TBI,
GFAP was able to discriminate between severe disability and persistent vegetative state, despite both
GFAP and S-100β being correlated with mortality [114]. A large, retrospective TBI outcome study [113]
found that biomarkers S-100β and NSE are independently correlated to long-term functional outcome,
but S-100β represents a more accurate outcome predictor and possibly a more clinically useful
biomarker than NSE for TBI patients. Neuron specific enolase (NSE) is a glycolytic enzyme released
into the extracellular space under pathological conditions during cell destruction. Levels are high in the
CSF, but the serum concentration depends on the state of the BBB [115], and extracranial contribution
is probably more problematic than S-100β. In pediatric TBI, NSE has been correlated with the Glasgow
Outcome Score (GOS) [116].
Summary: β-Amyloid Precursor Protein (β-APP), NSE, Neurofilament Protein (NF), Glial Fibrillary
Acidic Protein (GFAP) and S100 are critical biomarkers of neuronal death in TBI.
Table 1. Potential biomarkers of DAI.
Precursor Proteolytic System Subunits Potential Biomarkers
αII spectrin Caspase-3 and calpain Spectrin breakdown products (SBDP) SBDP145, SBDP150, SBDP120
Neurofilament protein (NF) Caspase and calpain
Light (NFL), medium (NFM),
and heavy (NFH) neurofilament
subunit protein
pNF-H
Glial fibrillary acidic
protein (GFAP) Calpain
GFAP breakdown products
(GFAP-BDP) GFAP-BDP38, GFAP-BDP44
Microtubule-associated
protein tau (MAP-tau) Caspase-3 and calpain Tau breakdown products (TauBDP) TauBDP45 TauBDP35
β-amyloid precursor
protein (β-APP) Caspase-3 Amyloid beta peptides Amyloid β peptide42 (Aβ42)
6. Diagnosis and Radiology
6.1. CT Scans
Unenhanced and Iodine contrast-enhanced brain CT scans are usually the first level of radiological
examination for the severely head-injured patients [117]. Because of its easy access and rapid
acquisition, a CT scan represents the imaging modality of choice for initial assessment of TBI and for
the detection of acute hemorrhagic lesions for surgical intervention. It is especially useful for detecting
intracranial traumatic pathologies in hemodynamically or neurologically unstable patients [118].
The Marshall classification shed the first light on the impact of CTs in the evaluation of the radiological
severity of head trauma [117]. It was based on the observations of the Traumatic Coma Data Bank
Study, and it described the condition of the basal cisterns, possible presence of midline shift, evacuated
versus non-evacuated intracranial mass lesions and possible bony fragments. The CT scan has
been improved [119] to show possible presence of intraventricular hemorrhage (IVH) and traumatic
subarachnoid hemorrhage (tSAH), in order to provide a four-feature tool (midline shift, basal cisterns,
IVH and tSAH) to predict post-traumatic morbidity and mortality. Computed tomography imaging
does not definitely provide precise clues for the assessment of DAI or disclose the possible presence of
DAI itself. However, it is a first-line examination for patients entering an Emergency Room, affected
by severe TBI. The importance of the evaluation of IVH lies in the demonstrated association of its
presence and severity as seen on the initial CT with DAI lesions and their severity as shown on
the subsequent MRI, especially in the corpus callosum [120,121]. The correlation may be due to
the shared shearing strain mechanism of subependymal vessels and mid-line brain structures’ axon
damage. This information from the initial CT could be useful for selecting patients who should
further undergo an MRI. Even if CT is highly sensitive in case of concurrent traumatic lacerations
and other primary intracranial traumatic lesions, it is known that less than 20% of DAI patients
present with macroscopically detectable “Stirch” hemorrhages; this methodology has the major
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limitation of underestimating the parenchymal effect of the head trauma and poorly discerns the
diffuse axonal injury, so MRI is necessary to detect lesions that may be correlated to clinical symptoms,
and that the initial CT is not able to explain [122]. Further investigations have produced different
CT scan scoring systems to finely evaluate the first CT scan after a TBI [123]. Among such systems,
the Rotterdam, Stockholm and Helsinki deserve a specific mention: the Rotterdam scoring system has
gained popularity following its validation by the IMPACT trial—basically, it reweights the components
of the Marshall system, evaluating such components by means of an arithmetic sum of single ordinal
subscales; the Stockholm system is focused on the presence/absence of tSAH, IVH and possible
intracranial traumatic blood collection in the same way as the Helsinki CT score.
6.2. MRI: Short-Term MRI and Follow-Up
Despite the limitations of applying MRI during the first weeks post-injury in patients who are
unstable or do not cooperate, it is a more sensitive method than CT for detecting DAI, confirming
the presence of small hemorrhagic lesions in the white matter of cerebral hemispheres, corpus
callosum and brainstem [124,125]. Indeed, traumatic microbleeds in the white matter are considered
radiological markers for DAI [126]. The use of MRI sequences sensitive to hemorrhages, such as
susceptibility-weighted imaging (SWI) and T2*-weighted gradient echo (T2*GRE) can confirm DAI
diagnosis [127–130]. MRI is also capable of detecting non-hemorrhagic lesions related to DAI, such
as widespread disruption of axons and local edema associated to axonal damage [10], with MRI
sequences like diffusion tensor imaging (DTI), diffusion weighted imaging (DWI), MR spectroscopy,
and conventional MR sequences [131–133].
T2-weighted and, particularly FLAIR sequences, provide good visualization of non-hemorrhagic
parenchymal lesions, but DWI has a greater sensitivity for identifying DAI as hyperintense lesions
(Figure 3) [134].
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Diffusion tensor magnetic resonance imaging (DTI) represents a promising method for the
non-invasive detection of the degree of fiber damage. A recent study [134] evaluated diffusion tensor
tractography (DTT) as an instrument for identifying diffuse axonal injury in nineteen patients with
acute, mild, and moderate traumatic brain injury (TBI), using fractional anisotropy (FA) that represents
the degree of alignment of the white matter tracts [135], and mean diffusivity (MD), which represents
the degree of overall restrictions to water diffusion, as a measure of the average diffusion in all
directions [136]. The reduction in FA and changes in MD were significant, compared with a control
group, in several tracts such as the corpus callosum, fornix, uncinate fasciculus, superior and posterior
thalamic radiations, and inferior longitudinal fasciculus. Furthermore, they observed a meaningful
correlation between FA and MD indices and the seriousness of post-concussive symptoms, indicating
their possible utility as predictors of long-term outcome.
In clinical practice, 1.5 T MRI seems to be sufficient for the detection of DAI-related micro-hemorrhagic
lesions. Nevertheless, T2*-weighted gradient-echo MRI at 3 T is found to be superior to MRI at 1.5 T
for this purpose. Therefore, it could be appropriate when there is a strong clinical suspicion of DAI
without evident lesions in routine MRI, and when a long interval since the trauma has passed [126].
In spite of this, patients with closed-head trauma suffering from post-traumatic cognitive
impairment may not present pathological findings at 1.5 or 3 T MRI [137]; MRI at higher field strength
with a better spatial resolution, such as 7 T MRI, is more sensitive in visualizing microhemorrhagic
DAI. The role of 7 T SWI has been investigated by Moenninghoff et al. [10] who stated its importance
as a tool for diagnostic in inconclusive or medicolegal cases.
Residues of microhemorrhage may last for months or years, though hemorrhagic DAI lesions
become less evident after three months [138,139].
Moen et al. [138] examined the evolution of TAI lesions during the first year post-injury using
conventional MRI in the early phase and at three and 12 months, demonstrated attenuation of volume
and number of non-hemorrhagic TAI lesions on FLAIR sequences during the first three months after
TBI. Brainstem lesions were often no longer visible, leading to a lower stage of TAI—this is an important
finding since brainstem lesions have been associated with poor outcomes [140].
In terms of long-term follow-up imaging, it should be considered that DAI may result in
atrophy [141]; moreover, in the chronic stages of a TBI white matter hyperintensities in FLAIR
sequences could be ascribed to post-traumatic gliosis [142].
Summary: CT scan is the golden standard for a first emergency level of examination. MRI performed
with contemporary sequences and methodology allows a more accurate definition of the damage on
the brain parenchyma.
7. Conclusions: What Is Currently Ascertained
DAI is caused by a blunt concussive trauma which applies strong rotational and translational
forces to the brain parenchyma, resulting in a diffuse disruption of the white matter axons. TBI results
in the delayed dysfunction and death of neuronal population near and distant to the site of injury.
This secondary phase of increased neuronal vulnerability contributes to many of the neurological
conditions associated with traumatic injury. DAI is not only caused by primary axotomy from
mechanical forces, but also from secondary axotomy due to a progressive molecular and cellular
cascade of pathologic changes within the axon after initial shear stress at the time of injury. Studies
support the role of an altered axonal calcium homeostasis in the mechanism of secondary damage of
axon, and suggest that calcium channel blockers that can alleviate the secondary damage, as well as
other mechanisms implied in the secondary injury, could be targeted as candidates of therapeutic
approaches. ROS-mediated axonal degeneration is mainly caused by extracellular Ca2+. Removal
of extracellular Ca2+, rather than a blockade of mitochondrial Ca2+ release, is an efficient strategy
in lowering intracellular Ca2+ and inhibiting spheroid formation. In vivo, calpain and calcineurin
inhibition is able to mitigate axonal degeneration. Oxidative stress with resulting damage of the
endogenous antioxidant defense mechanisms acts as a significant player in the secondary events
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leading to neuronal death. Increase in the defense mechanisms through the use of exogenous
antioxidants may be neuroprotective, particularly if they are given within the neuroprotective time
window [143,144]. A promising potential therapeutic target in DAI is to directly address mitochondria
related injury or to modulate energetic axonal energy failure [3]. mPTP is produced as a consequence
of a greater gathering of calcium and permits the movement of small molecules inside or outside
the mitochondria. mPTP participation in the axonal degeneration process has led to considering it
as a therapeutic goal in DAI. However, dietary supplementation with antioxidant and the use of
pharmacological agents targeting oxidative stress seem logical but the benefits of proven antioxidant
strategies have not been clearly demonstrated to date [145].
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